The Vancouver Lymphadenopathy-AIDS Study: 2. Seroepidemiology of HTLV-III antibody.
Testing for antibody to human T-lymphotropic retrovirus (HTLV-III) was carried out in 448 participants in the Vancouver Lymphadenopathy-AIDS (acquired immune deficiency syndrome) Study. The overall prevalence rate of seropositivity was 34%. Of 130 seronegative subjects followed for an average of 8.5 months, 14 became seropositive; thus, the approximate annual seroconversion rate was 15%. More than 100 male sexual partners in one's lifetime, frequent receptive anal intercourse, fisting, a history of gonorrhea or hepatitis, and frequent sexual contact in clubs were found to be independent risk factors for HTLV-III seropositivity.
Jeffries
E
E
Willoughby
B
B
Boyko
W J
WJ
Schechter
M T
MT
Wiggs
B
B
Fay
S
S
O'Shaughnessy
M
M
D000163:Acquired Immunodeficiency Syndrome / Q000097:blood / Q000150:complications / Q000453:epidemiology* / Q000276:immunology; D001955:British Columbia; D017977:Deltaretrovirus / Q000276:immunology*; D006716:Homosexuality; D006801:Humans; D008206:Lymphatic Diseases / Q000097:blood / Q000150:complications / Q000453:epidemiology* / Q000276:immunology; D008297:Male; D012192:Retroviridae Infections / Q000150:complications; D012306:Risk; D012725:Sexual Behavior